Compare AstraZeneca plc (AZN) vs AT&T Inc. (T) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

AT&T (T) trades at $21.57, up 2.06% today but near 52-week lows amid Starlink competition fears. The stock shows bearish technical signals with RSI at 97.16 suggesting overbought conditions. Fundamentally, T maintains strong profitability with a 16.94% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights SpaceX's satellite-to-phone ambitions creating sector-wide pressure, though AT&T continues innovation with 5G drone detection trials.

Despite near-term headwinds, AT&T presents value with a 5.3% dividend yield and low P/E of 7.26. The consensus price target of $26.43 implies 22.6% upside potential. Primary risks include Starlink disruption and telecom sector volatility, but strong cash flow generation and analyst buy ratings (41%) support a constructive long-term outlook for patient investors.